Ryzodeg 70/30 Market Report 2026

Ryzodeg 70/30 Market Overview

• The Ryzodeg 70/30 market growth in the historic period has been driven by rising prevalence of type 1 and type 2 diabetes, increased insulin therapy adoption • Market expansion is supported by increasing demand for patient-friendly insulin therapies, growing focus on long-acting insulin innovations • Growth Driver: Rising Prevalence Of Diabetes Driving Market Growth Due To Increasing Insulin Therapy Adoption • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ryzodeg 70/30 Market?

Ryzodeg 70/30 is a combination insulin consisting of 70% insulin degludec (long-acting) and 30% insulin aspart (rapid-acting). It is used to control blood sugar levels in people with type 1 or type 2 diabetes, providing both immediate and long-lasting effects. The main types of indications in ryzodeg 70/30 are type 1 diabetes and type 2 diabetes. Type 1 diabetes is an autoimmune condition where the body destroys insulin-producing cells in the pancreas, requiring lifelong insulin therapy for blood sugar management. It is distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and is used by various end users, such as hospitals and clinics, home care settings, and long-term care facilities.

What Is The Ryzodeg 70/30 Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for patient-friendly insulin therapies, growing focus on long-acting insulin innovations, expansion of home-based diabetes management, rising healthcare spending on chronic diseases, increasing adoption of digital diabetes monitoring. Major trends in the forecast period include increasing adoption of fixed-ratio combination insulins, rising preference for long-acting basal-bolus therapies, growing focus on simplified diabetes treatment regimens, expansion of pen-based insulin delivery formats, enhanced emphasis on glycemic stability.

Global Ryzodeg 70/30 Market Segmentation

1) By Indication: Type 1 Diabetes, Type 2 Diabetes 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Hospitals And Clinics, Home Care Settings, Long-Term Care Facilities

What Are The Drivers Of The Ryzodeg 70/30 Market?

Rising prevalence of diabetes is expected to propel the growth of the ryzodeg 70/30 market going forward. Diabetes is a chronic condition where the body either cannot produce enough insulin or cannot effectively use the insulin it produces, leading to high blood sugar levels. The rising prevalence of diabetes can be attributed to factors such as unhealthy diets, sedentary lifestyles, obesity, genetic predisposition, aging populations, and increased awareness and diagnosis of the condition. Ryzodeg 70/30, a combination insulin product, helps manage diabetes by providing both basal and bolus insulin action, allowing for better blood sugar control throughout the day and night, which is crucial for individuals with type 1 and type 2 diabetes to maintain stable glucose levels and improve overall glycemic control. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%. Therefore, the rising prevalence of diabetes is driving the growth of the ryzodeg 70/30 industry. The rising aging population is expected to propel the growth of the ryzodeg 70/30 market going forward. An aging population refers to a demographic shift where the proportion of elderly individuals increases due to longer life expectancy and lower birth rates, posing challenges to healthcare, pensions, and the workforce. The rising aging population can be attributed to factors such as increased life expectancy, declining birth rates, advances in healthcare and medical technologies, better sanitation, and socioeconomic changes. Ryzodeg 70/30 helps the aging population by providing simplified, flexible, and stable blood sugar control with a lower risk of hypoglycemia, improving diabetes management and overall quality of life. For instance, in January 2024, according to the Population Reference Bureau (PRB), a US-based non-profit organization, the population of Americans aged 65 and older is projected to increase by 47%, from 58 million in 2022 to 82 million by 2050. This demographic's share of the total population is expected to grow from 17% to 23% during the same period. Therefore, the rising aging population is driving the growth of the ryzodeg 70/30 industry. The rising healthcare expenditure is expected to propel the growth of the ryzodeg 70/30 market going forward. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on preventing, treating, and managing health conditions. Healthcare expenditure is increasing due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often come at higher costs, leading to greater overall spending in healthcare. Rising healthcare expenditure is expected to support the growth of ryzodeg 70/30 by enabling broader access to advanced diabetes therapies and facilitating investment in patient education, disease management programs, and innovative treatment options. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, the rising healthcare expenditure is driving the growth of the ryzodeg 70/30 industry.

Key Players In The Global Ryzodeg 70/30 Market

Major companies operating in the ryzodeg 70/30 market are Novo Nordisk A/S

Regional Insights

North America was the largest region in the ryzodeg 70/30 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Ryzodeg 70/30 Market?

The ryzodeg 70/30 market consists of sales of products including the flextouch pen, novopen 5, vial, cartridge, and kwikpen. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ryzodeg 70/30 Market Report 2026?

The ryzodeg 70/30 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ryzodeg 70/30 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.